Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

被引:98
|
作者
Norman, Jill [1 ]
机构
[1] UCL Med Sch, Div Med, UCL Ctr Nephrol, London NW3 2PF, England
关键词
Fibroblasts; Myofibroblasts; Fibrosis; Extracellular matrix; Epithelial-fibroblast interactions; Chronic kidney disease; ABNORMAL EXTRACELLULAR-MATRIX; GELATINASE-A MMP-2; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; PKD1; GENE; INTERSTITIAL FIBROSIS; TARGETED DISRUPTION; TISSUE INHIBITOR; EPITHELIAL-CELLS; RENAL FIBROSIS;
D O I
10.1016/j.bbadis.2011.06.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The age on onset of decline in renal function and end-stage renal disease (ESRD) in autosomal polycystic kidney disease (ADPKD) is highly variable and there are currently no prognostic tools to identify patients who will progress rapidly to ESRD. In ADPKD, expansion of cysts and loss of renal function are associated with progressive fibrosis. Similar to the correlation between tubulointerstitial fibrosis and progression of chronic kidney disease (CKD), in ADPKD, fibrosis has been identified as the most significant manifestation associated with an increased rate of progression to ESRD. Fibrosis in CKD has been studied extensively. In contrast, little is known about the mechanisms underlying progressive scarring in ADPKD although some commonality may be anticipated. Current data suggest that fibrosis associated with ADPKD shares at least some of the "classical" features of fibrosis in CKD (increased interstitial collagens, changes in matrix metalloproteinases (MMPs), over-expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), over-expression of plasminogen activator inhibitor-1 (PAI-1) and increased transforming growth factor beta (TGF beta) but that there are also some unique and stage-specific features. Epithelial changes appear to precede and to drive interstitial changes leading to the proposal that development of fibrosis in ADPKD is biphasic with alterations in cystic epithelia precipitating changes in interstitial fibroblasts and that reciprocal interactions between these cell types drives progressive accumulation of extracellular matrix (ECM). Since fibrosis is a major component of ADPKD it follows that preventing or slowing fibrosis should retard disease progression with obvious therapeutic benefits. The development of effective anti-fibrotic strategies in ADPKD is dependent on understanding the precise mechanisms underlying initiation and progression of fibrosis in ADPKD and the role of the intrinsic genetic defect in these processes. This article is part of a Special Issue entitled: Polycystic Kidney Disease. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:1327 / 1336
页数:10
相关论文
共 50 条
  • [11] HYPERURICEMIA IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE (ADPKD)
    TANGEL, DJ
    KAEHNY, WD
    DULEY, IT
    JOHNSON, AM
    GABOW, PA
    KIDNEY INTERNATIONAL, 1988, 33 (01) : 211 - 211
  • [12] Preventive project of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Esteban de la Rosa, Rafael J.
    Poyatos Andujar, Antonio Miguel
    Morales Garcia, Ana Isabel
    Martinez Navarro, Luis
    Garcia Valverde, Maria
    Bravo Soto, Juan Antonio
    NEFROLOGIA, 2021, 41 (06): : 704 - 706
  • [13] Interstitial inflammation in autosomal dominant polycystic kidney disease (ADPKD).
    Tao, YX
    Kim, J
    Schrier, RW
    Edelstein, CL
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 874A - 874A
  • [14] COMPUTED TOMOGRAPHY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Patil, Devendra
    Chitnis, Ashutosh
    Khaire, Hrishikesh
    Hira, Rajiv
    Yadav, Pankaj
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2015, 4 (101): : 16707 - 16708
  • [15] PARAMETERS ASSOCIATED WITH PROGRESSION, PROGNOSIS AND TOLVAPTAN INDICATION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Gkika, Vasiliki
    Louka, Michaela
    Fokas, Stavros
    Tigka, Eirini
    Drakopoulos, Angelos
    Markou, Niki
    Doumani, Georgia
    Kostopoulou, Myrto
    Tsagkatakis, Mihail
    Tsirpanlis, George
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I5 - I5
  • [16] Parameters Associated With Progression, Prognosis, and Tolvaptan Indication in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Gkika, Vasiliki
    Louka, Michaela
    Tigka, Eirini
    Drakopoulos, Angelos
    Kostopoulou, Myrto
    Tsirpanlis, George I.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 155 - 155
  • [17] Glis3 Is a Modifier of Cyst Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Wei, Zemeng
    Tian, Xin
    Rehman, Michael
    Dong, Ke
    Cai, Yiqiang
    Cordido, Adrian
    Somlo, Stefan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [18] Metabolomic Analysis of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): Associations with Disease Progression and Treatment
    Sundar, Shirin
    Roth, Sharin
    Hajarnis, Sachin S.
    Westcott-Baker, Lucas
    Mccormick, Linda
    Ramaswamy, Bharath
    Chapman, Arlene B.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 396 - 396
  • [19] Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD
    Dana Rizk
    Arlene Chapman
    Pediatric Nephrology, 2008, 23 : 1029 - 1036
  • [20] Kidney volume enlargement in unilateral autosomal dominant polycystic kidney disease (ADPKD)
    Poster, D.
    Krauer, F.
    Kistler, A.
    Weishaupt, D.
    Wuethrich, R. P.
    Serra, A.
    SWISS MEDICAL WEEKLY, 2008, 138 (47-48) : 11S - 11S